1
prof. Ján MojžišDepartment of Pharmacology,
Medical Faculty, P.J. Šafarik UniversityKošice
Drugs used to treat hypertension
2
Target-Organ Damage
• Brain: stroke, transient ischemic attack, dementia
• Eyes: retinopathy
• Heart: left ventricular hypertrophy, angina
• Kidney: chronic kidney disease
• Peripheral Vasculature: peripheral arterial disease
2
3
Adult Classification
ClassificationSystolic BP
(mmHg)Diastolic BP
(mmHg)
Normal < 120 and < 80
Prehypertension 120-139 or 80-89
Stage 1 hypertension
140-159 or 90-99
Stage 2 hypertension
> 160 or > 100
3
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206–1252.
4
Treatment Goals
• Reduce morbidity & mortality • Select drug therapy based on evidence
demonstrating risk reduction
4
Patient Population Target BP
Most patients < 140/90 mmHg
Diabetes mellitus < 130/80 mmHg
Chronic kidney disease <130/80 mmHg
5
Hypertension
Essential (primary)- most (90-95 %) patients with persistent arterial hypertension- genesis of hypertension unknown- predisposing factors:
Secondary- is secondary to some distinct diseases:
Renal + renovascular desease (artery stenosis)Hormonal defects (Cushing´s syndrome, pheochromocytoma)Mechanical defect (coarctation of aorta)Hypertension in pregnancyDrug-induced hypertension (sympatomimetics, glucocorticoids)Neurologic disease
susceptive(obesity, stress, salt intake, lack of Mg2+, K+, Ca2+, ethanol dose, smoking)
non-susceptive(positive family history, insulin resistance, age, sex, defect of local vasomotoric regualtion)
6
Treatment of hyperternsion
A: Non-pharmacological
Changes of lifestyl
7
Lifestyle Modifications
Modification RecommendationSystolic BP Reduction
(mm Hg)
Weight loss Maintain normal body weight (body mass index 18.5–24.9 kg/m2)
5–20 per 10-kg weight loss
DASH-type dietary patterns
Consume a diet rich in fruits, vegetables, and low-fat dairy products with a reduced content of saturated and total fat
8–14
Reduced salt intake
Reduce daily dietary sodium intake as much as possible, ideally to 65 mmol/day (1.5 g/day sodium, or 3.8 g/day sodium chloride)
2–8
Physical activity
Regular aerobic physical activity (at least 30 min/day, most days of the week)
4–9
Moderation of alcohol intake
Limit consumption to 2 drinks/day in men and 1 drink/day in women and lighter-weight persons
2–4
7DASH, Dietary Approaches to Stop Hypertension.
8
Standard drink
A standard drink is about 142 ml or 5 oz of wine (12% alcohol). 341 mL or 12 oz of beer (5% alcohol) 43 mL or 1.5 oz of spirits (40% alcohol).
9
10
B. Pharmacological
1. Diuretics
2. -blockers
3. ACE-I, blockers of AT1 receptor
4. Calcium channel blockers
5. Other
11
Diuretics
• Thiazide –chlorthalidone, hydrochlorothiazide (HCTZ),
indapamide, metipamid, clopamid
• Loop–bumetanide, furosemide, torsemide
• Potassium-sparing–spironolactone, amiloride
11
12
DIURETICS – cont.
- drugs of first choice for treating patients with mild hypertension often combined with another drug in treatment of more severe hypertension
THIAZIDES
- preferable (to loop diuretics) for the treatment of
uncomplicated hypertension
- given by mouth as a single morning dose (to avoid
nocturnal diuresis)
- begin to act within 1-2 hours and work for 12-24 hours
- treatment should be started using a low dose
13
Thiazides
Lumen –urine
Distal convoluted
tubule
Interstitium - blood
14
Mechanism of action:
lower blood pressure by reduction of blood volume and by direct vascular effect
- inhibition of sodium chloride transport in the early segment of the distal convoluted tubule natriuresis, decrease in preload and cardiac output - renal effect
- slow decrease of total peripheral resistance (raised initially) during chronic treatment, suggesting an action on resistance vessels - extrarenal effects
15
- metabolic and electrolyte changes
hyponatremia
hypokalemia (combine with potassium-sparing diuretics)
hypomagnesemia
hyperuricemia (most diuretics reduce urate clearance)
hyperglycemia
hypercalcemia (thiazides reduce urinary calcium ion
clearance)
- idiosyncratic reactions (rashes - may be photosensitiv,
purpura)
- lithium toxicity with concurrent administration
Adverse effects
16
LOOP DIURETICS
- useful in hypertensive patients with moderate or severe renal impairment, or in patients with hypertensive heart failure
- relatively short-acting (diuresis occurs over the 4 hours following a dose) used in hypertension if response to thiazides is inadequate
Mechanism of action:
- they inhibit the co-transport of Na+, K+ and 2Cl-
- of Ca2+ and Mg2+ excretion
- they have useful pulmonary vasodilating effects (unknown mechanism)
17
Lumen –urine
Thick ascending limb
Furosemide
Interstitium - blood
18
- hypokalemic metabolic alkalosis ( excretion of K+)
- ototoxicity (dose dependent, reversible)
- hypomagnesemia
- hyperuricemia (block of uric acid tubular secretion)
- sulfonamide allergy
- risk of dehydration (> 4 L urine/ 24 h)
Important drug interaction may occurs if loop diuretic is given with Li+ (antimanic drug). Decrease of Na+ reabsorption can lead to increase of Li+ reabsorption toxicity.
Adverse effects
19
Potassium-sparing diuretics
act in the distal tubule and the collecting tubule to inhibit Na+ reabsorption, K+ secretion, H+ secretion
they are often used with a thiazide diuretic to spare potassium
Spironolactone
- it is an aldosterone antagonist
- is useful in patients with high level of aldosterone
- it has low diuretic efficacy its advantage is sparing of potassium
- it is often used with loop or thiazide diuretics
20
Potassium-sparing diuretics – cont.
Amiloride
- it has similar potassium-spring action to that of spironolactone
- its efect is independent on aldosterone concentration
- it si also frequently used with other diuretics
Adverse effects:may cause hyperkalemia especially in combination with ACE inhibitor, angiotensin-receptor blocker or potassium supplements
21
-adrenoreceptor antagonists
22
β-Receptors• Distributed throughout the body
– concentrate differently in certain organs & tissues
• β1 receptors:
– heart, kidney
– stimulation increases HR, contractility, renin release
• β2 receptors:
– lungs, liver, pancreas, arteriolar smooth muscle
– stimulation causes bronchodilation & vasodilation
– mediate insulin secretion & glycogenolysis
• β3 receptors:
– adipose tissue, skeletal muscle
– stimulation causes lipolysis in adipose tissue thermogenesis in skeletal muscle
23
- Negative chronotropic & inotropic cardiac effects
- Inhibit renin release (weak association with antihypertensive effect)
- Membrane-stabilizing action on cardiac cells at high enough doses (?)
Possible mechanisms include: -adrenoceptors located on sympathetic nerve terminals can promote noradrenaline release, and this is prevented by -receptor antagonists
Mechanism of action
24
cardio-selective:
1 blockers atenolol, metoprolol
1 blockers with ISAacebutol
cardio non-selective:
1 + 2 blockers metiprolol, propranolol, nadolol
1 + 2 blockers with ISA pindolol, bopindolol
1+2+ 1 blockers labetalol, carvedilol
-adrenoreceptor antagonists – cont.
25
Cardioselective β-Blockers
• Greater affinity for β1 than β2 receptors
– inhibit β1 receptors at low to moderate dose
– higher doses block β2 receptors
• Safer in patients with bronchospastic disease, peripheral arterial disease, diabetes– may exacerbate bronchospastic disease when
selectivity lost at high doses – dose where selectivity lost varies from patient to patient
• Generally preferred β-blockers
25
26
Nonselective β-Blockers
• Inhibit β1 & β2 receptors at all doses
• Can exacerbate bronchospastic disease
• Additional benefits in:– essential tremor– migraine headache– thyrotoxicosis
26
27
Adverse effects
- bradycardia
- AV blockade
- CHF
- asthmatic attack (in patients with airway disease)
- hypoglycemia in patients with DM
- cold extremities
- CNS adverse effects - sedation, fatigue, and sleep alterations.
-adrenoreceptor antagonists – cont.
28
Angiotensin-converting enzyme inhibitors (ACE-I)
29
- hypertension where thiazide diuretics and -blockers
are contraindicated
- useful in hypertensive patients with heart failure
(beneficial effect)
- diabetic nephropathy
Captopril, enalapril, quinapril, lisinopril, perindopril, ramipril
Indications
30
ACE
Angiotensin I(inactive)
Angiotensin II(vasoconstrictor)
Bradykinine(vasodilator)
Inactive metabolites
ACE-I
31
RENIN
Angiotensinogen Angiotensin I
ANGIOTENSIN II
ACE
Vasoconstriction Proliferative Action
Vasodilatation Antiproliferative Action
AT1 AT2RECEPTORS
ACE Inhibitors
Effect of ACE-I
32
Decrease noradrenaline release reduction of sympathetic activity (use is not associated with reflex tachycardia)
Inhibition of aldosterone secretion contributes to the antihypertensive effects of ACE-I
Influence on the arteriolar and left ventricular remodelling that are believed to be important in the pathogenesis of human essential hypertension and post-infarction state
Dilatation of arteriol reduction of peripheral vascular resistance, blood pressure and afterload
Increase of Na+ and decrease of K+ excretion in kidney
ACE-I – cont.
33Summary of the three major effects of angiotensin II and the mechanisms that mediate them.
34
Pharmacokinetics
- active when administered orally- most of ACE-Is are highly polar, eliminated in the urine, without CNS penetration
captopril, lisinopril - active per seenalapril, quinapril - prodrugs require metabolic activation
enalapril, quinapril and lisinopril - given once dailycaptopril - administered twice daily
ACE-I – cont.
35
Drug Duration of effect (hours)
Short-act. captopril 6-8Medially-act. enalapril 12
quinapril
Long-act.
perindopril
24lisinopril
spirapril
ramipril
ACE-I – cont.
36
Adverse effects
-well tolerated
First dose hypotension - particularly in those receiving diuretic therapy; the first dose should preferably be given at bedtime.Dry cough - the most frequent (5-30%) symptom; Urticaria and angioneurotic edema - kinin concentrations urticarial reactions and angioneurotic edema Functional renal failure - mainly in patients with bilateral renal artery stenosis Fetal injury - results in oligohydramnios, craniofacial malformations
ACE-I – cont.
37
Hyperkalemia – monitor !!
- ACE-Is cause a modest increase in plasma potassium
as a result of reduced aldosterone secretion.
- potassium accumulation may be marked, especially if
the patient is consuming high-potassium diet and/or
potasssium- sparing diuretics.
ACE-I – cont.
38
BLOCKERS OF AT1 RECEPTOR
39
losartan, valosartan, irbesartan
-it competitively inhibit angiotensin II at its AT1 receptor
site
Mechanisms responsible for antihypertensive effect:
inhibition of direct vasoconstrictive effect of A-II
decrease of sympathetic nerve activity
decrease of A-II-mediated aldosterone release
decrease of RAS activity in CNS
decrease of smooth muscle and cardiac hypertrophy and
hyperplasia
40
RENIN
Angiotensinogen Angiotensin I
ANGIOTENSIN II
ACEOther paths
Vasoconstriction Proliferative Action
Vasodilatation Antiproliferative Action
AT1 AT2
AT1 Receptor
AntagonistsRECEPTORS
Inhibition of the effects of angiotensin II
AT II AT II
41
angiotensinogen
angiotensin I
angiotensin II
renin
ACE
non-renin proteasescathepsin
t-PA
Other paths for A-II synthesis
42
Blockers of AT1 receptor – cont.
losartan
- prodrug (metabolite is 10-40x potent than losartan)
- rapid absorption, food has minor effect on the absorption, bound to albumin
valsartan
- active drug (40, 000 x greater affinity to AT-1 than AT-2)
rapid absorption, food has minor effect on the absorption, bound to albumin
43
Blockers of AT1 receptor – cont.
Clinical use in hypertension
losartan
- aditive effect to hydrochlorthiazide (HCTZ)
- fixed dose combination: losartan 50 mg + 12.5 mg HCTZ
valsartan
- in placebo-controlled trials 80 mg decrease syst. and diastol. pressure aproximately about 7-10 mm Hg
- equivalent to 20 mg of enalapril or 10 mg of lisinopril
44
- these drugs lower blood pressure as the ACE
inhibitors and have the advantage of much lower
incidence of adverse effects resulting from
accumulation of bradykinin (cough, angioneurotic
oedema)
- they cause fetal renal toxicity (like that of the ACE
inhibitors)
- these drugs reduce aldosterone levels and cause
potassium accumulation (attainment of toxic levels -
hazardous in patients with renal impairment)
BLOCKERS OF AT1 RECEPTOR – cont.
45
Renin Inhibitor
• 1st agent FDA approved in 2007: aliskiren• Inhibits angiotensinogen to angiotensin I conversion• FDA approved as monotherapy & combination therapy
with other antihypertensives • combination with other antihypertensives including
amlodipine, HCTZ, ACEIs/ARBs• Does not block bradykinin breakdown
– less cough than ACE Inhibitors• Adverse effects: orthostatic hypotension, hyperkalemia
46
Calcium channel blockers
(CCBs)
47
1. dihydropyridines (nifedipine, nicardipine, amlodipine)
2. benzothiazepines (diltiazem)3. phenylalkylamines (verapamil)4. tetralol (mibefradil)
- they block voltage-dependent „L-type“ calcium channels
relaxation of smooth muscle vasodilation reduce
peripheral vascular resistance reduction of BP
- negatively inotropic drugs
they differ in selectivity for calcium channels in vascular
smooth muscles and cardiac tissues
48
Dihydropyridine CCBs
• Dihydropyridines more potent peripheral vasodilators than non-dihydropyridines – may cause more reflex sympathetic discharge:
tachycardia, dizziness, headaches, flushing, peripheral edema
• Additional benefits in Raynaud’s syndrome
• Effective in older patients with isolated systolic hypertension
48
49
• Indication: all grades of essential hypertension
• alone (nifedipine, amlodipine) in patients with mild hypertension for patients in whom thiazide diuretics and b-blockers are contraindicated
• combinations• angina (with -blockers)
50
Non-dihydropyridine CCBs
• extended release products preferred for hypertension
• Block cardiac SA (diltiazem) or AV (verapamil) nodes: reduce HR
• May produce heart block
• Additional benefits in patients with atrial tachyarrhythmia
50
51
Unwanted effects
- reflex tachycardia if nifedipine-like drugs are used
- constipation
- dizziness
- headache, flushing, ankle swelling
- fatigue
- AV block
52
Mibefradil
- newest calcium blocker
- blockade of L and T channels
- do not possess the negative inotropic effect of verapamil and diltiazem
- it can depres cardiac conductance
- it is not associated vith peripheral edema and reflex tachycardia of the dihydropyridines
- antihypertensive effect is evident within the first week of therapy
- efficacy may be diminished in dietary sodium restriction and diuretic co-therapy (both stimulate renin activity)
53
Other
)-adrenoreceptor antagonists
b)centrally acting symatomimetics
c)direct vasodilators
54
Mechanism of action:
- vasodilatation (reduce vascular resistence) and decreased blood pressure by antagonizing of tonic action of noradrenaline on 1 receptors (vascular smooth muscle)
nonselective a. short-term action:
phentolamineb: long-term action
phenoxybenzamineselective
a. short-term action:prazosin, uradipil
b. long-acting doxazosin, terazosin
-adrenoreceptor antagonists
55
Adverse reaction
- the main manifestations are:
- drowsiness, weakness, orthostatic hypotension (first dose – bedtime administration)
- for the nonselective agents, tachycardia - in patients with coronary disease, angina may be precipitated by the tachycardia
- oral administration of any of these drugs can cause nausea, vomiting, diarrhoea
- urinary incontinence
- priapism, nasal congestion
-adrenoreceptor antagonists – cont.
56
2-agonists
Clonidine, Moxonidine
direct 2-agonist, imidazol receptor agonists (I1)
Methyldopa
false neurotransmitter corbadrine (2-agonist)
Centrally acting drugs
- limited use in the treatment of hypertension.
- methyldopa hypertension during pregnancy
- methyldopa causes symptoms of drowsiness and fatigue that are intolerable to many adult patients in long-term use
- they are seldom used to treat essential hypertension
- clonidine is potent but poorly tolerated (rebound hypertension, if it is discontinued abruptly, is an uncommon but severe problem)
57
Adverse effects
- drowsiness, fatigue (esp. methyldopa), depression,
nightmares
- nasal congestion, anticholinergic symptoms
(constipation, bradycardia) – clonidine
- dry mouth
- hepatitis, drug fever (methyldopa)
- sexual dysfunction, salt and water retention
- hypertensive rebound associated with anxiety, sweating,
tachycardia and extrasystoles (rarely hypertensive
crisis)
Centrally acting drugs – cont.
58
Direct Arterial Vasodilators • Direct arterial smooth muscle relaxation causes
antihypertensive effect (little or no venous vasodilation)– reduce impedence to myocardial contractility
– potent reductions in perfusion pressure activate baroreceptor reflexes
– baroreceptor activation: compensatory increase in sympathetic outflow; tachyphylaxis can cause loss of antihypertensive effect• counteract with concurrent β-blocker • clonidine if β-blocker contraindicated
58
59
Vasodilators – cont.
- drugs which dilate blood vessels (and decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:
* release of nitric oxide * opening of potassium channels
60
Sodium nitroprusside
- short-acting agent (few minutes) administrated by
infusion in hypertensive emergencies (hypertensive
encephalopathy, shock, cardiac dysfunction) for max
24 hours (risk of cyanide cummulation toxicity)
- photodeactivation
- - adverse effects: too rapid reduction of BP, nausea,
palpitation, dizziness
Drugs acting via NO release
61
Minoxidil, diazoxide, nicorandil, pinacidil, cromakalim
Minoxidil
- therapy of severe hypertension resistant to other drugs
- prodrug its metabolite (minoxidil sulfate) is a potassium channel opener ( repolarization + relaxation of vascular smooth muscle)
- more effect on arterioles than on veins
- orally active
- Adverse effects: Na+ and water retention → coadministration with -blocker and diuretic, oedemas, hypertrichosis, breast tenderness
Openers of potassium channels
62
Diazoxide
-given by rapid iv. injection (less than 30 seconds) in hypertensive emergencies
glucose intolerance due to reduced insulin secretion (used in patients with inoperable insulinoma)
- adverse effects: Na+ and water retention, hyperglycaemia, hirsutism
Openers of potassium channels – cont.
63
Possible combinations of antihypertensives
Thiazides
ACE-I
β-blockers AT1 RB
CCBα- blockers
The most rationale combinations
64
Treatment of Adults with Systolic/Diastolic Hypertension
without Other Compelling IndicationsTARGET <140/90 mmHg
INITIAL TREATMENT AND MONOTHERAPY
* BBs are not indicated as first line therapy for age 60 and above
Beta-blocker*
Long-actingCCB
Thiazide ACE-I ARB
Lifestyle modificationtherapy
ACEI and ARB are contraindicated in pregnancy and caution is required in prescribing to women of child bearing potential
65
Treatment of Hypertension in association with Diabetes Mellitus: Summary
More than 3 drugs may be needed to reach target values for diabetic patients
If Creatinine over 150 µmol/L or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control of volume is desired
Threshold equal or over 130/80 mmHg and TARGET below 130/80 mmHg
Diabetes
withNephropathy
Combination(Effective
2-drug combination)
ACE Inhibitoror ARB
withoutNephropathy
1. ACE-Inhibitor or ARB
or
2. Thiazide diuretic or DHP-CCB
66
Treatment of Hypertension in Patients with Non Diabetic Chronic Kidney Disease
Target BP: Nondiabetic: < 130/80 mmHg
Chronic kidney disease and proteinuria *
1. ACE-I2. Alternate if ACE-I not tolerated: ARB
Combination with other agents
Additive therapy: Thiazide diuretic.Alternate: If volume overload: loop diuretic
* albumin:creatinine ratio [ACR] > 30 mg/mmol or urinary protein > 500 mg/24hr
67
Thiazides — particularly indicated for hypertension in the elderly; a contra-indication is gout;
-blockers — indications include myocardial infarction, angina; compelling contra-indications include asthma, heart block;
ACE inhibitors — indications include heart failure, left ventricular dysfunction and diabetic nephropathy; contra-indications include renovascular disease and pregnancy; when thiazides and beta-blockers are contra-indicated, not tolerated, or fail to control blood pressure
Angiotensin-II receptor antagonists are alternatives for those who cannot tolerate ACE inhibitors because of persistent dry cough, but they have the same contra-indications as ACE inhibitors;
Calcium-channel blockers. a) Dihydropyridine calcium-channel blockers are valuable in isolated systolic hypertension in the elderly when a low-dose thiazide is contra-indicated or not tolerated. b) ‘Rate-limiting’ calcium-channel blockers (e.g. diltiazem, verapamil) may be valuable in angina; contra-indications include heart failure and heart block;
-blockers — a possible indication is prostatism; a contra-indication is urinary incontinence.
68
Hypertensive EmergencyDrug Dose Onset
(min)Duration
(min)Adverse Effects Special Indications
Sodium nitroprusside
0.25–10 mcg/kg/min intravenous infusion
Immediate 1–2 Nausea, vomiting, muscle twitching, sweating, thiocyanate and cyanide intoxication
Most hypertensive emergencies; caution with high intracranial pressure, azotemia, or in chronic kidney disease
Nicardipine hydrochloride
5–15 mg/h intravenous
5–10 15–30; may
exceed 240
Tachycardia, headache, flushing, local phlebitis
Most hypertensive emergencies except acute heart failure; caution with coronary ischemia
Clevidipine butyrate
1-2 mg/h intravenous infusion; may double dose every 90 sec initially; maximum: 32 mg/h; typical maintenance dose: 4 to 6 mg/h
2-4 5-15 Headache, syncope, dyspnea, nausea, vomiting
Most hypertensive emergencies except severe aortic stenosis; caution with heart failure
Fenoldopam mesylate
0.1–0.3 mcg/kg/min intravenous infusion
< 5 30 Tachycardia, headache, nausea, flushing
Most hypertensive emergencies; caution with glaucoma
69
Hypertensive EmergencyDrug Dose Onset
(min)Duration
(min)Adverse Effects Special
IndicationsNitroglycerin 5–100 mcg/min
intravenous infusion2–5 5–10 Headache, vomiting,
methemoglobinemia, tolerance with prolonged use
Coronary ischemia
Hydralazine hydrochloride
12–20 mg intravenous10–50 mg intramuscular
10–2020–30
60–240240–360
Tachycardia, flushing, headache vomiting, aggravation of angina
Eclampsia
Labetalol hydrochloride
20–80 mg intravenous bolus every 10 min; 0.5–2.0 mg/min intravenous infusion
5–10 180–360 Vomiting, scalp tingling, bronchoconstriction, dizziness, nausea, heart block, orthostatic hypotension
Most hypertensive emergencies except acute heart failure
Esmolol hydrochloride
250–500 mcg/kg/min intravenous bolus, then 50–100 mcg/kg/min intravenous infusion; may repeat bolus after 5 min or increase infusion to 300 mcg/min
1–2 10–20 Hypotension, nausea, asthma, first-degree heart block, heart failure
Aortic dissection; perioperative
69DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy:A Pathophysiologic Approach, 7th Edition: http://www.accesspharmacy.com/